Enopace Biomedical is a Biotechnology company that develops innovative, RF-operated active aortic neuromodulation systems for treating congestive heart failure patients. The company’s technology comprises a minimally invasive, implantable neurostimulator device designed to increase cardiac efficiency by reducing left-ventricular workload.
Enopace Biomedical was voted #1 medical innovation company at the annual Shark Tank Innovation Competition, Transcatheter Interventional Therapeutics (TCT) Congress, Denver, Colorado.